Premium
Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib‐resistant chronic myeloid leukaemia patient harbouring the BCR‐ABL1 T315I gatekeeper mutation
Author(s) -
Coude MarieMagdelaine,
Luycx Odile,
Cariou MarieEstelle,
Maarek Odile,
Dombret Hervé,
Cayuela JeanMichel,
Rea Delphine
Publication year - 2012
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2011.09016.x
Subject(s) - nilotinib , imatinib , medicine , philadelphia chromosome , dasatinib , myeloid leukemia , tyrosine kinase , cancer research , oncology , biology , genetics , chromosomal translocation , receptor , gene